Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study

Chaparro, M. ; Garre, A. ; Núñez Ortiz, A. ; Diz-Lois Palomares, M. T. ; Rodríguez, C. ; Riestra, S. ; Vela, M. ; Benítez, J. M. ; Fernández Salgado, E. ; Sánchez Rodríguez, E. ; Hernández, V. ; Ferreiro-Iglesias, R. ; Ponferrada Díaz, Á. ; Barrio. J. ; Huguet, J. M. ; Sicilia, B. ; Martín-Arranz, M. D. ; Calvet, X. ; Ginard, D. ; Alonso-Abreu, I. ; Fernández-Salazar, L. ; Varela Trastoy, P. ; Rivero, M. ; Vera-Mendoza, I. ; Vega, P. ; Navarro, P. ; Sierra, M. ; Cabriada, J. L. ; Aguas, M. ; Vicente, R. (Universidad de Zaragoza) ; Navarro-Llavat, M. ; Echarri, A. ; Gomollón, F. (Universidad de Zaragoza) ; Guerra del Río, E. ; Piñero, C. ; Casanova, M. J. ; Spicakova, K. ; Ortiz de Zarate, J. ; Torrella Cortés, E. ; Gutiérrez, A. ; Alonso-Galán, H. ; Hernández-Martínez, Á. ; Marrero, J. M. ; Lorente Poyatos, R. ; Calafat, M. ; Martí Romero, L. ; Robledo, P. ; Bosch, O. ; Jiménez, N. ; Esteve Comas, M. ; Duque, J. M. ; Fuentes Coronel, A. M. ; Sampedro, M. J. ; Sesé Abizanda, E. ; Herreros Martínez, B. ; Pozzati, L. ; Fernández Rosáenz, H. ; Crespo Suarez, B. ; López Serrano, P. ; Lucendo, A. J. ; Muñoz Vicente, M. ; Bermejo, F. ; Ramírez Palanca, J. J. ; Menacho, M. ; Carmona, A. ; Camargo, R. ; Torra Alsina, S. ; Maroto, N. ; Nerín de la Puerta, J. ; Castro, E. ; Marín-Jiménez, I. ; Botella, B. ; Sapiña, A. ; Cruz, N. ; Forcelledo, J. L. F. ; Bouhmidi, A. ; Castaño-Milla, C. ; Opio, V. ; Nicolás, I. ; Kutz, M. ; Abraldes Bechiarelli, A. ; Gordillo, J. ; Ber, Y. ; Torres Domínguez, Y. ; Novella Durán, M. T. ; Rodríguez Mondéjar, S. ; Martínez-Cerezo, F. J. ; Kolle, L. ; Sabat, M. ; Ledezma, C. ; Iyo E. ; Roncero, Ó. ; Irisarri, R. ; Lluis, L. ; Blázquez Gómez, I. ; Zapata, E. M. ; Alcalá, M. J. ; Martínez Pascual, C. ; Montealegre, M. ; Mata, L. ; Monrobel, A. ; Hernández Camba, A. ; Hernández, L. ; Tejada, M. ; Mir, A. ; Galve, M. L. ; Soler, M. ; Hervías, D. ; Gómez-Valero, J. A. ; Barreiro de Acosta, M. ; Rodríguez-Artalejo, F. ; García-Esquinas, E. ; Gisbert, J. P.

Resumen: (1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100, 000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Idioma: Inglés

DOI: 10.3390/jcm10132885

Año: 2021

Publicado en: Journal of Clinical Medicine 10, 13 (2021), 2885 [19 pp.]
ISSN: 2077-0383

Factor impacto JCR: 4.964 (2021)

Categ. JCR: MEDICINE, GENERAL & INTERNAL rank: 55 / 172 = 0.32 (2021) - Q2 - T1

Factor impacto CITESCORE: 4.4 - Medicine (Q2)

Factor impacto SCIMAGO: 1.04 - Medicine (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI16-01296
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FI17-00143

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)